New Zealand markets open in 9 hours 30 minutes

Incannex Healthcare Inc. (IXHL)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.9800-0.1400 (-4.49%)
At close: 04:00PM EDT
3.0700 +0.09 (+3.02%)
Pre-market: 08:11AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.1200
Open3.1400
Bid0.0000 x 0
Ask7.8000 x 100
Day's range2.9300 - 3.1401
52-week range0.8000 - 12.6800
Volume11,125
Avg. volume324,780
Market cap47.293M
Beta (5Y monthly)2.27
PE ratio (TTM)N/A
EPS (TTM)-0.8800
Earnings date26 Feb 2024 - 01 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder

    Appendix: Comparison of PsiGAD Treatments to Existing Registered Treatments for Anxiety Figure: meta-analysis(1) of psychotropic medications for GAD, as measured by the HAM-A; the best medication that was coded as having reliable (larger sample size) results in this analysis, quetiapine, has a between group difference in effect of -3.60 on the HAM-A. Note, some studies included in this meta-analysis were considered unreliable by the authors. Highlights: PsiGAD1 trial achieves primary endpoint; P

  • GlobeNewswire

    Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation

    MELBOURNE, Australia and NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex or the Company), a leading cannabinoid and psychedelic medicine biotechnology company, is pleased to announce the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse. The pre-IND teleconference included representatives f

  • GlobeNewswire

    Clarion Clinics Open for Psychedelic-Assisted Treatments

    Highlights: Clarion’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression, alongside extensive psychotherapy.Clarion Clinics’ built-for-purpose clinic in Melbourne is now open for treatment, and will begin screening patients immediately.Clarion Clinics represents Australia’s leading track record in psychedelic-assisted therapies, and has developed a best-practice model of